Vertex Pharmaceuticals IncorporatedVRTX
Price$522.81Intrinsic value$495.095% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $12.6B+14.2% YoYTTM through 30 Jun 2026
Net Income $4.4BTTM through 30 Jun 2026
Free Cash Flow $3.8BTTM through 30 Jun 2026

Margins

Current
Gross Margin86.2%
EBITDA Margin39.7%
Operating Margin3,810.0%
Net Margin35.0%

Returns

22.5%ROE
16.1%ROA
20.4%ROIC

Balance Sheet Health

Debt / Equity0.10x
Current Ratio3.02x
Net Debt-$5.1Bnet cash position
Cash & Equivalents$6.1B

Quality Metrics

Altman Z-Score13.13
Piotroski F-Score6 / 9
FCF Margin30.2%
Rule of 4034.9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $12B
Diluted EPS$17.17TTM
'19'20'21'22'23'24'25
FY2025: $15.32

Dividend

No dividend

Capital Allocation

Capex Intensity3.9%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.